Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017

Stefan Weisshaar1 · Brigitte Litschauer1 · Berthold Reichardt2 · Felix Gruber3 · Stefan Leitner3 · Sasa Sibinovic3 · Michael Kossmeier3 · Michael Wolzt1

Received: 11 February 2022 / Accepted: 27 April 2022 / Published online: 19 May 2022 © The Author(s) 2022

Abstract
Patients with hyperuricemia and gout are at an increased risk for cardiovascular (CV) disease. Inhibition of the xanthine oxidase with allopurinol or febuxostat have become the mainstay for urate lowering therapy. However, it has been suggested that febuxostat increases the risk for CV mortality as compared to allopurinol. The aim of this retrospective cohort study was to assess the CV risk among patients with febuxostat or allopurinol therapy. Patients who initiated urate lowering therapy with febuxostat or allopurinol between 2014 and 2017 were selected from the drug reimbursement database of the Austrian health insurances funds. The primary CV endpoint was a composite of angina pectoris, nonfatal myocardial infarction, nonfatal subarachnoid or cerebral hemorrhage, nonfatal ischemic stroke, or death from any cause. In total, 28,068 patients (62.1% male) with a mean age of 71 years were included. 7,767 initiated febuxostat treatment and 20,301 received allopurinol. The incidence rate per 100 patient-years of the composite primary endpoint was 448 (febuxostat) and 356 (allopurinol) with a corresponding adjusted hazard ratio (HR) of 0.58 (95% CI 0.53–0.63) for allopurinol vs. febuxostat initiators. Similar HR were found for secondary endpoints including all-cause mortality [0.61 (95% CI 0.55–0.68)] and separate analyses of cardiac events [0.48 (95% CI 0.38–0.61)] and ischemic stroke [0.47 (95% CI 0.36–0.61)]. Data from this Austrian population-based study suggests that febuxostat initiators are at an increased risk for nonfatal CV events or death from any cause as compared to those with allopurinol. This is consistent with CV concerns of other trials, which limited the broad therapeutic use of febuxostat.

Keywords Allopurinol · Cardiovascular disease · Febuxostat · Gout

Introduction
Gout is a common chronic inflammatory condition, which is associated with hyperuricemia resulting from a perturbed uric acid metabolism. Patients with gouty arthritis suffer from acute or episodic painful flares due to deposition of monosodium urate crystals in peripheral joints [1–3]. Both the prevalence and incidence of gout are increasing and epidemiologic data suggest numerous risk factors such as the aging of the population, lifestyle/alimentation changes, obesity, diabetes, or the use of diuretic medicines [4]. Further, patients with gout are considered to be at a higher risk for cardiovascular (CV) disease, chronic kidney disease, or premature mortality as compared to those without gout [4–6].

Pharmacological treatment strategies for hyperuricemia include, among others, administration of xanthine oxidase inhibitors (XOI) such as allopurinol or febuxostat. Both medicines are approved for lowering serum uric acid concentrations to prevent future flares [7]. Allopurinol and febuxostat improve hyperuricemia by impeding the formation of xanthine from hypoxanthine and of uric acid from xanthine, respectively [8]. Febuxostat is more potent than allopurinol and does not require dose adjustment in patients with mild to moderate impaired renal function [9–11]. However, data from clinical trials suggest that the rate of CV events in
patients treated with febuxostat is higher than in patients receiving allopurinol or placebo [10, 12]. Further, the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial has shown that febuxostat increased the risk for all-cause and CV mortality as compared to patients receiving allopurinol [13]. The US Food and Drug Administration (FDA) concluded accordingly that there is an increased risk for death with febuxostat and limited its therapeutic use [14]. In contrast, data from a large population-based trial in Korea did not show any differences on mortality or CV events in febuxostat-treated gout patients as compared to those receiving allopurinol [15].

The aim of the present retrospective epidemiological nation-wide study was to assess the effect of allopurinol or febuxostat treatment among Austrian patients with hyperuricemic conditions on CV event risk and mortality. CV events were defined as hospitalization due to angina pectoris, acute myocardial infarction (AMI), ischemic stroke, or subarachnoid or cerebral hemorrhage. Analysis was performed from an observational period of 4 years by evaluation of data derived from the Federation of Social Insurances.

**Methods**

The protocol of this retrospective study was approved by the Ethics Committee of the Medical University of Vienna, Austria (EK 2104/2018). The study conforms to the principles outlined in the Declaration of Helsinki including current revisions. The study period ranged from January 1, 2014 to December 31, 2017.

**Data source**

Austria’s health insurance system provides health-care benefits for residents who are assigned to one of the several health insurance funds according to their current or former employment, and province of residence. Information of medical treatment covered by the health insurance funds is recorded in the respective databases, comprises about 97% of the Austrian population and is reported to the Federation of Social Insurances. These data include, among others, demographics, medical discharge diagnoses of hospital stays using the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD 10) coding system and prescriptions of medicines reimbursed by the Austrian Social Insurances (i.e., all medicines with either costs that exceed the respective prescription charge [EUR 5.40—EUR 5.85 for 2014–2017] or which are prescribed to patients who are exempt of paying the prescription charge). For this retrospective cohort study, we utilized longitudinal pooled data from the Federation of Social Insurances for the period of January 1, 2014 to December 31, 2017. Data were pseudonymized to preserve patients’ privacy. Data storage and handling were in agreement with the applicable data protection laws.

**Study cohort**

Eligible patients were 18 years or older and initiated a urate-lowering therapy with febuxostat or allopurinol between January 1, 2014 and December 31, 2017. XOI initiators were defined as individuals who did not fill any prescription of febuxostat (ATC code: M04AA03) or allopurinol (ATC code: M04AA01) prior to 2014. Patients were required to receive at least six continuous dispensings of the respective XOI within the observational period. This inclusion criterion was introduced to establish a possible causal relationship between XOI intake and adverse cardiovascular events [16]. Individuals who received prescriptions for both XOI medicines during the period of interest or had a history of malignancy (ICD code: CXX) were excluded.

**Outcome definition**

The primary outcome parameter was defined as a composite end point of the first occurrence of hospitalization due to angina pectoris (ICD-10 code: I20), nonfatal myocardial infarction (I21), nonfatal subarachnoid (I60) or cerebral hemorrhage (I61), nonfatal ischemic stroke (I63), or death from any cause during XOI intake or within ≤ 180 days after discontinuation of the XOI medicines. Secondary end points included separate analyses of cardiac events (composite of I20 and I21), intracranial bleeds (composite of I60 and I61), ischemic stroke (I63), and all-cause mortality.

**Covariate assessment**

Variables that were potentially associated with the baseline risk regarding CV outcome parameters of interest and that have been recorded in the Federation of Social Insurances database were assessed at time of treatment initiation. These variables included demographics (age, sex) and medicines that are commonly prescribed for treatment of CV risk factors. The medicines served as surrogates for co-morbidities and included antihypertensive medicines (beta blocker [ATC code: C07], angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) [ATC code: C09]), antidiabetics (ATC code: A10), antiplatelet medicines (B01AC) and lipid-lowering agents (ATC code: C10). These variables were used as control variables to account for potential differences between the febuxostat and allopurinol cohort already present at treatment initiation. Other risk factors, such as
smoking behavior, or laboratory or other diagnostic tests were not included as these data are not available in the Federation of Social Insurances database.

**Statistical analysis**

Statistical evaluations were performed with R (Version 4.1.0). Continuous and categorical variables are described by means, standard deviations (SD), absolute frequencies and/or percentages. The survival time distribution was estimated using the Kaplan–Meier estimator. The median follow-up time was estimated by the inverse Kaplan–Meier method (i.e., by inverting the event indicator). Cox proportional-hazard regression models were applied to estimate the association between febuxostat or allopurinol use and the time to the first occurrence of the composite primary or secondary end point events. Cox regression models were controlled for sex, age, and concomitant medication at baseline (treatment initiation). Adjusted hazard ratios (HR) with 95% confidence intervals (CI) were computed for primary and secondary outcome parameter associated with febuxostat or allopurinol use. The follow-up time started the day after the index date (i.e., first dispensing of febuxostat or allopurinol) and continued until XOI medicine discontinuation + 180 days, occurrence of an end point event, or end of study follow-up. Patients without a primary end point event during the 4 year observational period had their data censored on December 31, 2017 (database lock). If febuxostat or allopurinol treatment was discontinued during the study period, patients were censored at 6 months (i.e., 180 days) after the last dispensing of the XOI medicines.

**Results**

**Cohort selection and patients’ characteristics**

Figure 1 shows the study cohort selection process. In total, 28,068 patients who received XOI treatment and met the inclusion criteria were identified. 7767 subjects were febuxostat initiators and 20,301 were treated with allopurinol, respectively.

Table 1 summarizes demographics and concomitant medication of the study cohorts. There were more male patients receiving febuxostat as compared to allopurinol. Allopurinol initiators had higher numbers of co-medication at baseline (treatment initiation) than febuxostat initiators. The median (95% confidence interval) follow-up time was 640 (628–654) days in the febuxostat cohort and 907 (901–914) days for allopurinol initiators.

**Risk of cardiovascular disease and mortality in febuxostat vs. allopurinol initiators**

Kaplan–Meier curves of survival probability for the composite cardiovascular end point are presented in Fig. 2. Table 2 summarizes incidence rates of primary and secondary end points, which were all higher—except for intracranial hemorrhage—in the febuxostat cohort as compared to allopurinol. Febuxostat treatment was associated with a
greater risk for composite cardiovascular events or death during treatment with febuxostat as compared to allopurinol (adjusted HR: 0.58; 95% CI 0.53–0.63; \( P < 0.001 \)). Likewise, a similar pattern was observed for cardiac events (myocardial infarction or angina pectoris), stroke or death, respectively (Table 2). The risk for intracranial hemorrhage was also numerically lower in the allopurinol cohort, but did not significantly differ between study cohorts.

Female patients were at lower risk for the combined primary end point (adjusted HR: 0.78; 95% CI 0.71–0.85; \( P < 0.001 \)), death (adjusted HR: 0.78; 95% CI 0.71–0.86; \( P < 0.001 \)), or myocardial infarction or angina pectoris (adjusted HR: 0.54; 95% CI 0.42–0.69; \( P < 0.001 \)). The risk for other secondary end points did not show an association with sex.

Treatment with ACE-I/ARB or lipid-lowering agents had protective effects on the composite primary end point or mortality. Beta-blockers, antidiabetic, or antiplatelet medicines were associated with an increased risk for occurrence of these end points. ACE-I/ARB, lipid-lowering medicines or antiplatelet drugs administration were associated with an increased risk of cardiac events (myocardial infarction or angina pectoris), while other concomitant medicines had no impact. Hospitalization for stroke or intracranial hemorrhage was not affected by the concomitant medication under study.

**Discussion**

Our findings show that treatment with febuxostat substantially increased the risk for death from any cause and non-fatal CV events except for intracranial hemorrhage. These findings are partly consistent with the results of the CARES trial, which led to warnings for the use of febuxostat in some jurisdictions [14]. CARES had higher numbers in both all-cause mortality and CV death in patients with febuxostat treatment as compared to allopurinol. Non-fatal CV events were similar between allopurinol and febuxostat in the CARES population. This is at variance with our results and may be due to a more diverse study population in the present study than in the CARES cohort, which required a history of CV disease as inclusion criteria [13]. Likewise, it cannot be excluded that subjects of our study population had insignificant symptoms of CV disease (e.g., mild angina pectoris) at baseline as in our database outpatient visits (e.g., at the cardiologist) are not recorded with diagnoses. Although CARES was conducted in a randomized controlled fashion, a selection bias cannot be excluded due to the high numbers of premature study drug discontinuation (57%) and of patients lost to follow-up (45%) [17].

Other data of retrospective population studies [15, 18] did not show any significant difference in CV disease or mortality end points in febuxostat vs. allopurinol initiators.
Notably, subjects in a Korean trial [15] were significantly younger than in our study cohort (60 vs. 71 years), which may have affected outcomes. We observed a more than two-fold higher incidence rate in the composite end point in both allopurinol and febuxostat initiators suggesting that included patients in our study cohorts were sicker. Likewise, this observation may be age-related but also due to differences in socioeconomic variables in Europe vs. Asia. However, co-variate assessment was limited since medical history data, results from laboratory analysis or secondary medical discharge diagnoses were not available for our analysis. Thus, data provided from hospitals to the Austrian insurance institutions may be incomplete and the most common prescribed medicines in Austria [19] were used as surrogates for co-morbidities.

Proportions of concomitant medication in allopurinol initiators were higher than in patients with febuxostat suggesting that patients treated with allopurinol had a higher number of co-morbidities. This finding is supported by the fact that costs for allopurinol are below Austria’s prescription charge and therefore primarily allopurinol dispensings to prescription fee exempted patients are recorded in the databases of insurance institutions. This population group has usually a lower income and it is generally known that a lower socioeconomic status is associated with a higher number of co-morbidities [20]. Although concomitant medication was statistically adjusted for in our analysis, a selection bias particularly in the allopurinol study cohort cannot be excluded and it is likely that patients with a lower socioeconomic status are overrepresented in allopurinol initiators.

An immortal time bias, which may have over- or underestimated the event rates in different study groups, cannot be excluded [21]. Although data from 2013 to 2017 was available, we introduced a “cooling-off phase” of one year and excluded subjects with XOI treatment before 2014 to provide more robust statistics. Both the duration of allopurinol/febuxostat intake or if patients had received any XOI treatment earlier would have remained unclear as numbers of prescriptions filled in 2012 or earlier were not available. Further, only patients were included who filled at least six continuous XOI prescriptions to provide an appropriate observational period of drug exposure.

Febuxostat has been shown to be a more potent urate lowering medicine than allopurinol [7] and there is evidence that an excessive lowering of serum urate levels (below 4–5 mg/dL) may increase the risk for CV events through mitigation of uric acid’s beneficial antioxidant effects [22–24]. It cannot be excluded that uric acid levels were excessively reduced by febuxostat resulting in a higher CV risk or mortality in febuxostat initiators, but this is unclear in the absence of serum urate levels. In CARES a higher proportion of patients achieved lower serum urate levels (<5 mg/
and design. Material preparation, data collection and analysis were performed by BR, FG, SL, SS and MK. The first draft of the manuscript was written by SW, and was reviewed and edited by BL and MW. All authors commented on previous versions of the manuscript, and read and approved the final manuscript.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by BR, FG, SL, SS and MK. The first draft of the manuscript was written by SW, and was reviewed and edited by BL and MW. All authors commented on previous versions of the manuscript, and read and approved the final manuscript.

Funding Open access funding provided by Medical University of Vienna. No funding was received for conducting this study.

Data availability The datasets generated and analyzed are available from the corresponding author upon reasonable request.

Declarations

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Consent to participate Since only anonymized data were used, informed consent by the insured individuals was not required.

Consent to publish Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Pascart T, Liote F (2019) Gout: state of the art after a decade of developments. Rheumatology (Oxford) 58:27–44. https://doi.org/10.1093/rheumatology/key002
2. Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, Sun L (2020) Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis 79:1014–1022. https://doi.org/10.1136/annrheumdis-2020-217050
3. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019) Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. Arthritis Rheumatol 71:991–999. https://doi.org/10.1002/art.40807
4. Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin North Am 40:155–175. https://doi.org/10.1016/j.rdc.2014.01.001
5. Cox P, Gupta S, Zhao SS, Hughes DM (2021) The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatol Int 41:1209–1219. https://doi.org/10.1007/s00296-021-04876-6
6. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T (2014) Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 10:654–661. https://doi.org/10.1038/nrrheum.2014.124
7. FitzGerald JD, Dalbeth N, Mikuls T, Briglardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna...
PP. Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T (2020) 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Rheumatol 72:879–895. https://doi.org/10.1002/acr.24180
8. Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87–114. https://doi.org/10.1124/pr.58.1.6
9. Edwards NL (2009) Febuxostat: a new treatment for hyperuricemia in gout. Rheumatology (Oxford) 48:ii15–ii19. https://doi.org/10.1093/rheumatology/kep088
10. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eastace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461. https://doi.org/10.1056/NEJMoa050373
11. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540–1548. https://doi.org/10.1002/art.24209
12. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C (2009) Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48:188–194. https://doi.org/10.1093/rheumatology/kep457
13. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators C (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200–1210. https://doi.org/10.1056/NEJMoa1710895
14. FDA (2019). FDA adds boxed warning for increased risk of death with gout medicine uloric (febuxostat). https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat. Accessed 28 Mar 2022
15. Kang EH, Choi HK, Shin A, Lee YJ, Lee EB, Song YW, Kim SC (2019) Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford) 58:2122–2129. https://doi.org/10.1093/rheumatology/kez189
16. Kim SC, Schneeweis S, Choudhry N, Liu J, Glynn RJ, Solomon DH (2015) Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med 128:653e657–653e616. https://doi.org/10.1016/j.amjmed.2015.01.013
17. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R (2018) New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol 70:1702–1709. https://doi.org/10.1002/art.40583
18. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC (2018) Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation 138:1116–1126. https://doi.org/10.1161/CIRCULATIONAHA.118.033992
19. PHARMIG (2020). Daten & Fakten 2020 Arzneimittel und Gesundheitswesen in Österreich. https://www.pharmig.at/media/2890/daten_und_fakten_2020_deutsch.pdf. Accessed 28 Mar 2022
20. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A (2009) Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol 6:712–722. https://doi.org/10.1038/nrcardio.2009.163
21. Yadav K, Lewis RJ (2021) Immortal time bias in observational studies. JAMA 325:686–687. https://doi.org/10.1001/jama.2020.9151
22. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanelis J, Watanabe S, Tuttle KR, Rodriguez-Iтурbe B, Herrera-Acosta J, Mazzali M (2003) Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183–1190. https://doi.org/10.1161/01.HYP.0000069700.62727.C5
23. Suliman ME, Johnson RJ, Garcia-Lopez E, Qureshi AR, Molinaei H, Carrero JJ, Heimbürger O, Barany P, Axelsson J, Lindholm B, Stenvinkel P (2006) J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 48:761–771. https://doi.org/10.1053/j.ajkd.2006.08.019
24. Odden MC, Amadu AR, Smit E, Lo L, Peralta CA (2014) Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis 54:550–557. https://doi.org/10.1053/j.ajkd.2014.04.024
25. Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweis S (2013) Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken) 65:2008–2014. https://doi.org/10.1002/acr.22207
26. Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11:437–441. https://doi.org/10.1038/nrrheum.2015.30
27. Varga Z, Sahrwari SRA, Vargova V (2017) Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus 9:e1144. https://doi.org/10.7759/cureus.1144

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.